This clinically relevant review focuses on recent findings concerning hepatitis B surface antigen (HBsAg) quantitation in untreated patients and treated patients with chronic hepatitis B. Recent studies and emerging data have shown that both HBsAg and hepatitis B virus (HBV) DNA levels decline durin
Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: Clinical considerations and disease burden
✍ Scribed by Francesco Torre; Monica Basso; Edoardo G. Giannini; Marcello Feasi; Silvia Boni; Alessandro Grasso; Pasqualina De Leo; Ferdinando Dodi; Maria Grazia Marazzi; Emilio Azzola; Valentina Bartolacci; Gianfranco Percario; Andrea Beltrame; Paolo Borro; Antonino Picciotto
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 128 KB
- Volume
- 81
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The aim of this study was to determine the prevalence of hepatitis B virus (HBV) infection in an Italian region, Liguria (1,572,000 inhabitants), by means of a network of 12 referral centers for liver diseases. All patients with HBV surface antigen followed throughout 2006 were included. Personal data, infectious status with risk factors, other non‐infectious risk factors for liver disease, clinical status, and treatment were the questionnaire. Four hundred forty‐five patients (71% male) were evaluated. Their median age was 48 years (range 5–84), and 83.4% were of Italian origin. Community‐acquired infection was the principal mode of HBV transmission (82.5%), followed by previous intravenous drug use (9.4%), perinatal transmission (6.3%), and transfusion‐associated transmission (1.8%). Hepatitis B e‐antigen was present in 20.4% of the patients, while co‐infections with hepatitis D virus and/or hepatitis C virus and/or human immunodeficiency virus (HIV) were observed in 18.7% of the patients. Chronic active hepatitis was present in 62.5% of the patients, cirrhosis in 13.5%, hepatocellular carcinoma in 2.2%, and 21.8% of the patients were inactive carriers of HBV. In all, 42.5% of the patients were treated with interferon or lamivudine and/or adefovir‐dipivoxil. Forty‐nine patients were co‐infected with HIV (86% on highly active antiviral therapy). Nevertheless, this study identified only 2.2% of the expected patients with HBV. Hence, it has to be reasoned that few potential infectious or treatable patients are referred to liver disease centers. HBV infection is still an underestimated health problem, and few potential infectious or treatable patients are referred to tertiary centers. J. Med. Virol. 81:1882–1886, 2009. © 2009 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
This clinically relevant review focuses on recent findings concerning hepatitis B surface antigen (HBsAg) quantitation in untreated patients and treated patients with chronic hepatitis B. Recent studies and emerging data have shown that both HBsAg and hepatitis B virus (HBV) DNA levels decline durin
In the June 2011 issue of HEPATOLOGY, in the article entitled ''Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review'' (volume 53, pages 2121-2129) the data in Tables 2 and3 are to be corrected as listed below: On page 2124, under the heading '
## Abstract The clinical outcomes of 2,054 renal recipients were examined retrospectively based on pre‐transplant hepatitis B surface antigen (HBsAg) status to investigate the efficacy of lamivudine treatment in HBsAg positive recipients. Pre‐transplant HBsAg positivity was documented in 66 recipie